SOCS3 Attenuates Dexamethasone-Induced M2 Polarization by Down-Regulation of GILZ via ROS- and p38 MAPK-Dependent Pathways.
Hana JeongHyeyoung YoonYerin LeeJun Tae KimMoses YangGayoung KimBom JungSeok-Hee ParkChoong-Eun LeePublished in: Immune network (2022)
Suppressors of cytokine signaling (SOCS) have emerged as potential regulators of macrophage function. We have investigated mechanisms of SOCS3 action on type 2 macrophage (M2) differentiation induced by glucocorticoid using human monocytic cell lines and mouse bone marrow-derived macrophages. Treatment of THP1 monocytic cells with dexamethasone (Dex) induced ROS generation and M2 polarization promoting IL-10 and TGF-β production, while suppressing IL-1β, TNF-α and IL-6 production. SOCS3 over-expression reduced, whereas SOCS3 ablation enhanced IL-10 and TGF-β induction with concomitant regulation of ROS. As a mediator of M2 differentiation, glucocorticoid-induced leucine zipper (GILZ) was down-regulated by SOCS3 and up-regulated by shSOCS3. The induction of GILZ and IL-10 by Dex was dependent on ROS and p38 MAPK activity. Importantly, GILZ ablation led to the inhibition of ROS generation and anti-inflammatory cytokine induction by Dex. Moreover, GILZ knock-down negated the up-regulation of IL-10 production induced by shSOCS3 transduction. Our data suggest that SOCS3 targets ROS- and p38-dependent GILZ expression to suppress Dex-induced M2 polarization.
Keyphrases
- cell death
- dna damage
- high glucose
- reactive oxygen species
- diabetic rats
- endothelial cells
- poor prognosis
- drug induced
- low dose
- adipose tissue
- rheumatoid arthritis
- high dose
- anti inflammatory
- oxidative stress
- mesenchymal stem cells
- cell cycle arrest
- transforming growth factor
- bone marrow
- mass spectrometry
- signaling pathway
- cell proliferation